UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma

Cancer discovery, 2024-09, Vol.14 (9), p.1577-1580

2024

Volltextzugriff (PDF)

Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3

Cell death & disease, 2024-09, Vol.15 (9), p.690-13, Article 690

2024

Volltextzugriff (PDF)

TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma

PloS one, 2024-09, Vol.19 (9), p.e0310889

2024

Volltextzugriff (PDF)

The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody

BMC infectious diseases, 2024-07, Vol.24 (1), p.715-10, Article 715

2024

Volltextzugriff (PDF)

Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis

Oncology reports, 2024-10, Vol.52 (4), Article 133

2024

Volltextzugriff (PDF)

Comparison of B-Cell Lupus and Lymphoma Using a Novel Immune Imbalance Transcriptomics Algorithm Reveals Potential Therapeutic Targets

Genes, 2024-09, Vol.15 (9), p.1215

2024

Volltextzugriff (PDF)

Autonomic dysfunction as manifestation of ICANS: A case report

Medicine (Baltimore), 2024-09, Vol.103 (36), p.e38659

2024

Volltextzugriff (PDF)

Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report

Anti-cancer drugs, 2024-10, Vol.35 (9), p.878-881

2024

Volltextzugriff (PDF)

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma

Journal of nanobiotechnology, 2024-08, Vol.22 (1), p.475-16, Article 475

2024

Volltextzugriff (PDF)

Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy

Molecular cancer, 2024-07, Vol.23 (1), p.144-25, Article 144

2024

Volltextzugriff (PDF)

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

Virology journal, 2024-09, Vol.21 (1), p.212-8, Article 212

2024

Volltextzugriff (PDF)

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

International journal of molecular sciences, 2024-08, Vol.25 (15), p.8306

2024

Volltextzugriff (PDF)

A pre-B acute lymphoblastic leukemia cell line model reveals the mechanism of thalidomide therapy-related B-cell leukemogenesis

The Journal of biological chemistry, 2024-08, Vol.300 (8), p.107578, Article 107578

2024

Volltextzugriff (PDF)

A nontandem novel compound chimeric antigen receptor redirected to target CD20‐CD19 positive B‐cell acute leukemias and B‐cell lymphoma

Clinical and translational medicine, 2024-07, Vol.14 (7), p.e1743-n/a

2024

Volltextzugriff (PDF)

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data

International journal of molecular sciences, 2024-09, Vol.25 (17), p.9736

2024

Volltextzugriff (PDF)

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy

BMC cancer, 2024-08, Vol.24 (1), p.984-7, Article 984

2024

Volltextzugriff (PDF)

Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L

Cancer reports, 2024-09, Vol.7 (9), p.e2150-n/a

2024

Volltextzugriff (PDF)

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol

PloS one, 2024-08, Vol.19 (8), p.e0308247

2024

Volltextzugriff (PDF)

Advances in biology, diagnosis and treatment of DLBCL

Annals of hematology, 2024-09, Vol.103 (9), p.3315-3334

2024

Volltextzugriff (PDF)

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study

Hematological oncology, 2024-11, Vol.42 (6), p.e3314

2024

Volltextzugriff (PDF)

FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis

Cancer biology & therapy, 2024-12, Vol.25 (1), p.2403197

2024

Volltextzugriff (PDF)

A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma

Scientific reports, 2024-09, Vol.14 (1), p.21184-15, Article 21184

2024

Volltextzugriff (PDF)

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Journal of hematology and oncology, 2024-08, Vol.17 (1), p.69-5

2024

Volltextzugriff (PDF)

Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1

Cell death & disease, 2024-08, Vol.15 (8), p.561-16, Article 561

2024

Volltextzugriff (PDF)

A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma

Journal of medicinal chemistry, 2024-09, Vol.67 (17), p.15428-15437

2024

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

Neu hinzugefügt... seit 90 Tagen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(87)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(81)
Science & Technology
(57)
Life Sciences & Biomedicine
(55)
Female
(45)
Male
(44)
Lymphoma
(43)
Middle Aged
(36)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(33)
Aged
(30)
Oncology
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Adult
(24)
Patients
(23)
Cell Line, Tumor
(22)
Leukemia
(22)
Chemotherapy
(20)
B-Cell Lymphoma
(19)
Lymphocytes B
(19)
Medical Prognosis
(19)
Animals
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(27)

Menü

Weitere Dienste

Einstellungen

Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma

Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3

TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma

The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody

Histone deacetylase inhibitor and PD‑1 blockade synergistically inhibit B‑cell lymphoma progression in mice model by promoting T‑cell infiltration and apoptosis

Comparison of B-Cell Lupus and Lymphoma Using a Novel Immune Imbalance Transcriptomics Algorithm Reveals Potential Therapeutic Targets

Autonomic dysfunction as manifestation of ICANS: A case report

Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma

Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy

Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia

A pre-B acute lymphoblastic leukemia cell line model reveals the mechanism of thalidomide therapy-related B-cell leukemogenesis

A nontandem novel compound chimeric antigen receptor redirected to target CD20‐CD19 positive B‐cell acute leukemias and B‐cell lymphoma

Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy

Dexamethasone Inhibits the Growth of B‐Lymphoma Cells by Downregulating DOT1L

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol

Advances in biology, diagnosis and treatment of DLBCL

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study

FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis

A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1

A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma

Aktive Filter

Suchergebnisse filtern